Market Cap 72.04M
Revenue (ttm) 400,000.00
Net Income (ttm) -18.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,595.00%
Debt to Equity Ratio 0.00
Volume 2,794,800
Avg Vol 856,098
Day's Range N/A - N/A
Shares Out 49.68M
Stochastic %K 55%
Beta 1.31
Analysts Strong Sell
Price Target $5.53

Company Profile

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies agai...

Industry: Biotechnology
Sector: Healthcare
Phone: 979 446 0027
Website: ibioinc.com
Address:
11750 Sorrento Valley Road, Suite 200, San Diego, United States
Retail_Lives_Matter
Retail_Lives_Matter Aug. 19 at 11:01 AM
$IBIO do something you POFS
0 · Reply
BIOCOIN
BIOCOIN Aug. 19 at 8:29 AM
$IBIO bullish
0 · Reply
DSB1
DSB1 Aug. 19 at 3:29 AM
$IBIO Let's get back to $3.82
0 · Reply
DSB1
DSB1 Aug. 18 at 5:59 PM
$IBIO High volume today.
1 · Reply
browne321
browne321 Aug. 18 at 3:47 PM
$IBIO It's been handling itself pretty well.
0 · Reply
DSB1
DSB1 Aug. 18 at 1:28 PM
$IBIO Insider sentiment for Ibio Inc (IBIO) is Positive, fueled by high-impact open-market purchases from insiders. This confidence appears to be a broad consensus, with 11 different insiders buying. Over the last year, insiders have collectively bought or received $7.43M worth of shares and sold $0 across 100 transactions. However, focusing on high-impact open-market transactions, insiders purchased $1.41M and sold $73.9K worth of Ibio Inc stocks. The most recent trade was made 18 days ago by Carr Molly (Chief Medical Officer), who was awarded shares worth approximately $602.0K. The overall evaluation results in a strongly positive Insider Power Score, as the system found the trades or insider related actions from key insiders to be more positive than negative.
0 · Reply
WZMAN7227
WZMAN7227 Aug. 18 at 12:34 PM
$IBIO 71.23%
0 · Reply
DSB1
DSB1 Aug. 18 at 3:27 AM
$IBIO The overall pattern is substantially more buying than selling. MarketBeat's current compilation reports 26 institutional buyers versus only 2 sellers over the last 12 months, representing about $26.27 million of institutional inflows versus $1.23 million of outflows.
0 · Reply
DSB1
DSB1 Aug. 18 at 3:23 AM
$IBIO IBIO institutional movement: 🤑 Affinity Asset Advisors 3,107,200 +1,050,000 🟢 +51% Frazier Life Sciences 1,953,467 ~0 ⚪ Held EcoR1 Capital 1,583,000 −645,000 🔴 −28.9% Millennium Management 1,549,900 +1,549,900 🟢 NEW Vanguard Capital Management LLC 1,088,300 +1,088,300 🟢 NEW Balyasny Asset Management 1,011,000 −85,200 🔴 −7.8% Ikarian Capital 957,062 increased 🟢 Citadel Advisors 956,400 +956,400 🟢 NEW SIO Capital Management 904,300 +164,300 🟢 +22.2% Marshall Wace 620,602 +499,316 🟢 +411.7% ADAR1 Capital 469,878 +64,300 🟢 +15.9% Susquehanna 412,700 +412,700 🟢 NEW Two Sigma 408,858 −47,500 🔴 −10.4% Walleye Capital 388,554 +190,179 🟢 +95.9% Geode Capital 387,600 +165,000 🟢 +74.1% Noesis Capital 311,500 +87,300 🟢 +38.9% Bank of America 290,413 +174,620 🟢 +150.8% Boothbay Fund Management 254,400 essentially unchanged ⚪ SilverArc Capital 226,000 +120,000 🟢 +113.2% BlackRock 131,215 +88,488 🟢 +207.1%
0 · Reply
Stanman13
Stanman13 Aug. 17 at 2:24 PM
$IBIO Let's go!
0 · Reply
Latest News on IBIO
iBio appoints Molly Carr as chief medical officer

2026-08-04T13:15:57.000Z - 15 days ago

iBio appoints Molly Carr as chief medical officer

LLY


iBio announces new preclinical data from IBIO-610 study

2026-07-01T11:30:17.000Z - 7 weeks ago

iBio announces new preclinical data from IBIO-610 study


iBio initiated with an Outperform at Raymond James

2026-06-08T10:37:48.000Z - 2 months ago

iBio initiated with an Outperform at Raymond James


iBio to Participate in Upcoming Healthcare Investor Conferences

Jun 2, 2026, 4:01 PM EDT - 2 months ago

iBio to Participate in Upcoming Healthcare Investor Conferences


iBio doses first participant in IBIO-600 trial

2026-06-02T11:44:33.000Z - 2 months ago

iBio doses first participant in IBIO-600 trial


iBio, Inc. Slides: Corporate presentation

May 15, 2026, 7:00 AM EDT - 3 months ago

iBio, Inc. Slides: Corporate presentation


iBio reports Q3 EPS (7c), consensus (6c)

2026-05-12T21:36:01.000Z - 3 months ago

iBio reports Q3 EPS (7c), consensus (6c)


iBio, Inc. Earnings release: Q3 2026

May 12, 2026, 4:00 PM EDT - 3 months ago

iBio, Inc. Earnings release: Q3 2026


iBio, Inc. Quarterly report: Q3 2026

May 12, 2026, 4:00 PM EDT - 3 months ago

iBio, Inc. Quarterly report: Q3 2026


iBio, Inc. Transcript: Status update

Apr 8, 2026, 2:00 PM EDT - 4 months ago

iBio, Inc. Transcript: Status update


Biotech Alert: Searches spiking for these stocks today

2026-03-30T16:21:02.000Z - 5 months ago

Biotech Alert: Searches spiking for these stocks today

ACOG


iBio, Inc. Transcript: Study update

Mar 17, 2026, 4:00 PM EDT - 5 months ago

iBio, Inc. Transcript: Study update


iBio to provide update on cardiopulmonary program

2026-03-16T20:40:52.000Z - 5 months ago

iBio to provide update on cardiopulmonary program


iBio, Inc. Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 5 months ago

iBio, Inc. Slides: Corporate presentation


iBio initiated with a Buy at JonesResearch

2026-03-02T21:34:02.000Z - 6 months ago

iBio initiated with a Buy at JonesResearch


iBio files $200M mixed securities shelf

2026-02-27T21:36:51.000Z - 6 months ago

iBio files $200M mixed securities shelf


Biotech Alert: Searches spiking for these stocks today

2026-02-27T16:00:56.000Z - 6 months ago

Biotech Alert: Searches spiking for these stocks today


iBio, Inc. Registration statement: Registration Filing

Feb 27, 2026, 7:00 AM EST - 6 months ago

iBio, Inc. Registration statement: Registration Filing


iBio to Participate in Upcoming Investor Conferences

Feb 24, 2026, 7:00 AM EST - 6 months ago

iBio to Participate in Upcoming Investor Conferences


iBio reports Q2 EPS (9c), consensus (6c)

2026-02-10T21:13:10.000Z - 6 months ago

iBio reports Q2 EPS (9c), consensus (6c)


iBio, Inc. Quarterly report: Q2 2026

Feb 10, 2026, 4:00 PM EST - 6 months ago

iBio, Inc. Quarterly report: Q2 2026


iBio, Inc. Earnings release: Q2 2026

Feb 10, 2026, 4:00 PM EST - 6 months ago

iBio, Inc. Earnings release: Q2 2026


iBio, Inc. Registration statement: Registration Filing

Jan 30, 2026, 7:00 AM EST - 7 months ago

iBio, Inc. Registration statement: Registration Filing


iBio prices 11.06M shares at $2.35 in private placement

2026-01-09T12:13:56.000Z - 7 months ago

iBio prices 11.06M shares at $2.35 in private placement


iBio Announces $26 Million Private Placement

Jan 9, 2026, 7:00 AM EST - 7 months ago

iBio Announces $26 Million Private Placement


Biotech Alert: Searches spiking for these stocks today

2026-01-08T17:16:04.000Z - 7 months ago

Biotech Alert: Searches spiking for these stocks today


iBio initiated with an Outperform at LifeSci Capital

2025-12-18T14:06:19.000Z - 8 months ago

iBio initiated with an Outperform at LifeSci Capital

ARWR WVE


iBio initiated with an Outperform at LifeSci Capital

2025-12-18T13:41:09.000Z - 8 months ago

iBio initiated with an Outperform at LifeSci Capital


Biotech Alert: Searches spiking for these stocks today

2025-12-11T16:45:34.000Z - 8 months ago

Biotech Alert: Searches spiking for these stocks today

CAMP


iBio, Inc. Slides: Corporate presentation

Nov 17, 2025, 7:00 AM EST - 9 months ago

iBio, Inc. Slides: Corporate presentation


iBio, Inc. Earnings release: Q1 2026

Nov 12, 2025, 4:00 PM EST - 9 months ago

iBio, Inc. Earnings release: Q1 2026


iBio, Inc. Quarterly report: Q1 2026

Nov 12, 2025, 4:00 PM EST - 9 months ago

iBio, Inc. Quarterly report: Q1 2026


iBio, Inc. Proxy statement: Proxy Filing

Oct 6, 2025, 8:00 AM EDT - 11 months ago

iBio, Inc. Proxy statement: Proxy Filing


iBio, Inc. Slides: Corporate Presentation

Sep 16, 2025, 7:00 AM EDT - 1 year ago

iBio, Inc. Slides: Corporate Presentation


iBio, Inc. Annual report: Q4 2025

Sep 5, 2025, 9:00 AM EDT - 1 year ago

iBio, Inc. Annual report: Q4 2025


iBio, Inc. Earnings release: Q4 2025

Sep 5, 2025, 9:00 AM EDT - 1 year ago

iBio, Inc. Earnings release: Q4 2025


iBio Announces Closing of $50 Million Public Offering

Aug 25, 2025, 7:00 AM EDT - 1 year ago

iBio Announces Closing of $50 Million Public Offering


iBio Announces Pricing of $50 Million Public Offering

Aug 19, 2025, 8:01 AM EDT - 1 year ago

iBio Announces Pricing of $50 Million Public Offering


iBio Announces Proposed Public Offering

Aug 18, 2025, 4:01 PM EDT - 1 year ago

iBio Announces Proposed Public Offering


iBio, Inc. Transcript: Study Update

Jun 24, 2025, 8:30 AM EDT - 1 year ago

iBio, Inc. Transcript: Study Update


iBio, Inc. Press release: Study Update

Jun 24, 2025, 8:30 AM EDT - 1 year ago

iBio, Inc. Press release: Study Update


iBio, Inc. Slides: Study Update

Jun 24, 2025, 8:30 AM EDT - 1 year ago

iBio, Inc. Slides: Study Update


iBio, Inc. Registration statement: Registration Filing

Jun 13, 2025, 8:00 AM EDT - 1 year ago

iBio, Inc. Registration statement: Registration Filing


iBio Reports Fiscal Third Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 1 year ago

iBio Reports Fiscal Third Quarter 2025 Financial Results


iBio, Inc. Quarterly report: Q3 2025

May 2, 2025, 8:00 AM EDT - 1 year ago

iBio, Inc. Quarterly report: Q3 2025


iBio, Inc. Earnings release: Q3 2025

May 2, 2025, 8:00 AM EDT - 1 year ago

iBio, Inc. Earnings release: Q3 2025


iBio to Begin Trading on the Nasdaq Stock Exchange

Feb 19, 2025, 4:05 PM EST - 1 year ago

iBio to Begin Trading on the Nasdaq Stock Exchange


iBio Reports Fiscal Second Quarter 2025 Financial Results

Feb 10, 2025, 4:05 PM EST - 1 year ago

iBio Reports Fiscal Second Quarter 2025 Financial Results


iBio, Inc. Quarterly report: Q2 2025

Feb 10, 2025, 4:00 PM EST - 1 year ago

iBio, Inc. Quarterly report: Q2 2025


iBio, Inc. Earnings release: Q2 2025

Feb 10, 2025, 4:00 PM EST - 1 year ago

iBio, Inc. Earnings release: Q2 2025


iBio, Inc. Registration statement: Registration Filing

Jan 31, 2025, 7:00 AM EST - 1 year ago

iBio, Inc. Registration statement: Registration Filing


iBio Reports Fiscal First Quarter 2025 Financial Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

iBio Reports Fiscal First Quarter 2025 Financial Results


iBio, Inc. Quarterly report: Q1 2025

Nov 12, 2024, 4:00 PM EST - 1 year ago

iBio, Inc. Quarterly report: Q1 2025


iBio, Inc. Earnings release: Q1 2025

Nov 12, 2024, 4:00 PM EST - 1 year ago

iBio, Inc. Earnings release: Q1 2025


iBio, Inc. Proxy statement: Proxy Filing

Oct 10, 2024, 8:00 AM EDT - 2 years ago

iBio, Inc. Proxy statement: Proxy Filing


iBio, Inc. Earnings release: Q4 2024

Sep 20, 2024, 4:00 PM EDT - 2 years ago

iBio, Inc. Earnings release: Q4 2024


iBio, Inc. Annual report: Q4 2024

Sep 20, 2024, 4:00 PM EDT - 2 years ago

iBio, Inc. Annual report: Q4 2024


iBio, Inc. Registration statement: Registration Filing

Jul 25, 2024, 8:00 AM EDT - 2 years ago

iBio, Inc. Registration statement: Registration Filing


iBio, Inc. Registration statement: Registration Filing

Jul 3, 2024, 8:00 AM EDT - 2 years ago

iBio, Inc. Registration statement: Registration Filing


iBio Closes Sale of Manufacturing Facility in Texas

Jun 3, 2024, 7:00 AM EDT - 2 years ago

iBio Closes Sale of Manufacturing Facility in Texas


iBio, Inc. Quarterly report: Q3 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

iBio, Inc. Quarterly report: Q3 2024


iBio, Inc. Earnings release: Q3 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

iBio, Inc. Earnings release: Q3 2024


iBio, Inc. Registration statement: Registration Filing

Apr 16, 2024, 8:00 AM EDT - 2 years ago

iBio, Inc. Registration statement: Registration Filing


iBio stock nearly tripled on Wednesday: here's why

Mar 27, 2024, 2:43 PM EDT - 2 years ago

iBio stock nearly tripled on Wednesday: here's why


iBio, Inc. Transcript: Collaboration

Mar 27, 2024, 8:30 AM EDT - 2 years ago

iBio, Inc. Transcript: Collaboration


iBio, Inc. Press release: Collaboration

Mar 27, 2024, 8:30 AM EDT - 2 years ago

iBio, Inc. Press release: Collaboration


iBio Announces $15.0 Million Private Placement

Mar 26, 2024, 7:35 PM EDT - 2 years ago

iBio Announces $15.0 Million Private Placement


iBio, Inc. Quarterly report: Q2 2024

Feb 9, 2024, 4:00 PM EST - 2 years ago

iBio, Inc. Quarterly report: Q2 2024


iBio, Inc. Earnings release: Q2 2024

Feb 9, 2024, 4:00 PM EST - 2 years ago

iBio, Inc. Earnings release: Q2 2024


iBio Announces Participation in 23rd Annual PepTalk Conference

Jan 16, 2024, 8:15 AM EST - 2 years ago

iBio Announces Participation in 23rd Annual PepTalk Conference


iBio Amends and Extends Maturity of Credit Agreement

Dec 26, 2023, 7:15 AM EST - 2 years ago

iBio Amends and Extends Maturity of Credit Agreement


iBio, Inc. Announces Pricing of $4.5 Million Public Offering

Dec 5, 2023, 8:00 AM EST - 2 years ago

iBio, Inc. Announces Pricing of $4.5 Million Public Offering


iBio, Inc. Registration statement: Registration Filing

Nov 30, 2023, 7:00 AM EST - 2 years ago

iBio, Inc. Registration statement: Registration Filing


iBio Announces Reverse Stock Split

Nov 27, 2023, 5:20 PM EST - 2 years ago

iBio Announces Reverse Stock Split


iBio, Inc. Quarterly report: Q1 2024

Nov 14, 2023, 7:00 AM EST - 3 years ago

iBio, Inc. Quarterly report: Q1 2024


iBio, Inc. Earnings release: Q1 2024

Nov 14, 2023, 7:00 AM EST - 3 years ago

iBio, Inc. Earnings release: Q1 2024


iBio, Inc. Registration statement: Registration Filing

Oct 27, 2023, 8:00 AM EDT - 3 years ago

iBio, Inc. Registration statement: Registration Filing


iBio, Inc. Proxy statement: Proxy Filing

Oct 26, 2023, 8:00 AM EDT - 3 years ago

iBio, Inc. Proxy statement: Proxy Filing


iBio, Inc. Proxy statement: Proxy Filing

Oct 16, 2023, 8:00 AM EDT - 3 years ago

iBio, Inc. Proxy statement: Proxy Filing


iBio Explains Recent Filing of Registration Statement

Oct 2, 2023, 6:45 AM EDT - 3 years ago

iBio Explains Recent Filing of Registration Statement


iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

Sep 27, 2023, 4:19 PM EDT - 3 years ago

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K


iBio, Inc. Annual report: Q4 2023

Sep 27, 2023, 4:00 PM EDT - 3 years ago

iBio, Inc. Annual report: Q4 2023


iBio Announces Amendment to Credit Agreement with Woodforest

Sep 21, 2023, 4:05 PM EDT - 3 years ago

iBio Announces Amendment to Credit Agreement with Woodforest


iBio, Inc. Registration statement: Registration Filing

Aug 7, 2023, 8:00 AM EDT - 3 years ago

iBio, Inc. Registration statement: Registration Filing


Retail_Lives_Matter
Retail_Lives_Matter Aug. 19 at 11:01 AM
$IBIO do something you POFS
0 · Reply
BIOCOIN
BIOCOIN Aug. 19 at 8:29 AM
$IBIO bullish
0 · Reply
DSB1
DSB1 Aug. 19 at 3:29 AM
$IBIO Let's get back to $3.82
0 · Reply
DSB1
DSB1 Aug. 18 at 5:59 PM
$IBIO High volume today.
1 · Reply
browne321
browne321 Aug. 18 at 3:47 PM
$IBIO It's been handling itself pretty well.
0 · Reply
DSB1
DSB1 Aug. 18 at 1:28 PM
$IBIO Insider sentiment for Ibio Inc (IBIO) is Positive, fueled by high-impact open-market purchases from insiders. This confidence appears to be a broad consensus, with 11 different insiders buying. Over the last year, insiders have collectively bought or received $7.43M worth of shares and sold $0 across 100 transactions. However, focusing on high-impact open-market transactions, insiders purchased $1.41M and sold $73.9K worth of Ibio Inc stocks. The most recent trade was made 18 days ago by Carr Molly (Chief Medical Officer), who was awarded shares worth approximately $602.0K. The overall evaluation results in a strongly positive Insider Power Score, as the system found the trades or insider related actions from key insiders to be more positive than negative.
0 · Reply
WZMAN7227
WZMAN7227 Aug. 18 at 12:34 PM
$IBIO 71.23%
0 · Reply
DSB1
DSB1 Aug. 18 at 3:27 AM
$IBIO The overall pattern is substantially more buying than selling. MarketBeat's current compilation reports 26 institutional buyers versus only 2 sellers over the last 12 months, representing about $26.27 million of institutional inflows versus $1.23 million of outflows.
0 · Reply
DSB1
DSB1 Aug. 18 at 3:23 AM
$IBIO IBIO institutional movement: 🤑 Affinity Asset Advisors 3,107,200 +1,050,000 🟢 +51% Frazier Life Sciences 1,953,467 ~0 ⚪ Held EcoR1 Capital 1,583,000 −645,000 🔴 −28.9% Millennium Management 1,549,900 +1,549,900 🟢 NEW Vanguard Capital Management LLC 1,088,300 +1,088,300 🟢 NEW Balyasny Asset Management 1,011,000 −85,200 🔴 −7.8% Ikarian Capital 957,062 increased 🟢 Citadel Advisors 956,400 +956,400 🟢 NEW SIO Capital Management 904,300 +164,300 🟢 +22.2% Marshall Wace 620,602 +499,316 🟢 +411.7% ADAR1 Capital 469,878 +64,300 🟢 +15.9% Susquehanna 412,700 +412,700 🟢 NEW Two Sigma 408,858 −47,500 🔴 −10.4% Walleye Capital 388,554 +190,179 🟢 +95.9% Geode Capital 387,600 +165,000 🟢 +74.1% Noesis Capital 311,500 +87,300 🟢 +38.9% Bank of America 290,413 +174,620 🟢 +150.8% Boothbay Fund Management 254,400 essentially unchanged ⚪ SilverArc Capital 226,000 +120,000 🟢 +113.2% BlackRock 131,215 +88,488 🟢 +207.1%
0 · Reply
Stanman13
Stanman13 Aug. 17 at 2:24 PM
$IBIO Let's go!
0 · Reply
Retail_Lives_Matter
Retail_Lives_Matter Aug. 16 at 1:24 AM
$IBIO A few other links also show up in public materials:  iBio’s partnering page explicitly lists Eli Lilly among its collaborations.   iBio’s October 2024 corporate deck placed “Eli Lilly Partnership” alongside other partnering items, indicating a formal business relationship rather than just shared personnel.   Separately, current and former iBio leadership includes people who worked at Eli Lilly, which reinforces a broader talent connection between the companies.
2 · Reply
Retail_Lives_Matter
Retail_Lives_Matter Aug. 16 at 1:20 AM
$IBIO 2/2 * Strategic Alignment (Obesity): Eli Lilly’s heavy focus on the obesity drug market—driven by the success of Zepbound and a robust pipeline of next-generation candidates—creates a high-value environment for the drug discovery technologies and AI-driven platforms offered by partners like iBio. * AI Technology Integration: Eli Lilly is actively investing in AI for drug discovery, including its proprietary TuneLab platform, a co-innovation lab with NVIDIA, and partnerships with organizations like OpenAI and Insilico Medicine. This focus aligns with iBio’s own strategy of using AI-driven antibody discovery to accelerate therapeutic development, suggesting a potential technical synergy.
0 · Reply
Retail_Lives_Matter
Retail_Lives_Matter Aug. 16 at 1:20 AM
$IBIO 1/2 * Executive Leadership: Martin B. Brenner, iBio’s CEO, previously held leadership positions at Eli Lilly. * Medical Leadership: Molly Carr, iBio’s Chief Medical Officer, served in senior roles at Eli Lilly before joining iBio. * Strategic Collaboration: iBio has publicly referenced a partnership with Eli Lilly in its corporate materials, though specific details regarding the scope of this collaboration remain limited.
0 · Reply
Stanman13
Stanman13 Aug. 15 at 5:53 PM
$IBIO 92k+ watchers and price leveled out.. plus: "Strong Buy" rating, with average price targets around five dollars forty cents, suggesting significant upside from current levels. Hopefully I get in before the next ride up!
0 · Reply
DSB1
DSB1 Aug. 14 at 8:35 PM
$IBIO Put all of this together — 600 + 610 + amylin + bispecific + additional AstralBio work + sophisticated biotech investors + senior hiring + active partnership discussions — and I think the more interesting thesis is becoming not merely “Will IBIO-600 work?” It's becoming: “Is iBio quietly assembling an obesity franchise?”
0 · Reply
Stanman13
Stanman13 Aug. 14 at 7:45 PM
$IBIO 👁️ bio
0 · Reply
WZMAN7227
WZMAN7227 Aug. 14 at 2:54 PM
$IBIO another dumb move 😂
0 · Reply
TortillaDePatata
TortillaDePatata Aug. 14 at 9:01 AM
$IBIO Something is cooking. You know, they know, I know.
1 · Reply
MicsMugz
MicsMugz Aug. 13 at 9:34 AM
$IBIO Next $1.55 Load up after it breaks.
1 · Reply
Rower5oh
Rower5oh Aug. 12 at 11:45 PM
$IBIO I believe the addition of Dr Carr is a very significant event. Why would she jump ship from Lilly to go to what is essentially a start up? She has a tremendous amount of experience in this field and it is a coup to get someone of her caliber. Makes me think that Lilly is more than a passive observer in iBio’s progress. Perhaps they know they will be bringing Dr Carr back to Lilly in the near future. Time will tell, but I am feeling a distinct building of momentum
1 · Reply
HappyGentelmen
HappyGentelmen Aug. 12 at 6:38 AM
$TPST Will there be another day with gains of 4,000% or more here? $BNTX $IBIO $IBM
1 · Reply
Rower5oh
Rower5oh Aug. 12 at 1:57 AM
$IBIO https://lnkd.in/p/eW3pqi55
0 · Reply